Literature DB >> 18418345

Rotavirus vaccination coverage and adherence to the Advisory Committee on Immunization Practices (ACIP)-recommended vaccination schedule--United States, February 2006-May 2007.

.   

Abstract

Worldwide, rotavirus is the leading cause of severe gastroenteritis in children aged <5 years. In February 2006, a new human-bovine rotavirus vaccine, RotaTeq (Merck & Co., Inc., Whitehouse Station, New Jersey), was recommended by the Advisory Committee on Immunization Practices (ACIP) for routine vaccination of U.S. infants. Three doses of RotaTeq are recommended at ages 2, 4, and 6 months. The first dose should be administered between ages 6 and 12 weeks, and vaccination should not be initiated for infants aged >12 weeks. Subsequent doses should be administered at 4-10 week intervals, with all doses administered by age 32 weeks. This schedule is consistent with the ages at which RotaTeq was administered during prelicensure trials, and ACIP has recommended that RotaTeq only be administered at the ages for which safety and efficacy data are available. In 1999, a previous rhesus-human rotavirus vaccine, RotaShield (Wyeth Laboratories, Inc., Marietta, Pennsylvania), was withdrawn voluntarily from the U.S. market by the manufacturer because it was associated with intussusception, a form of bowel obstruction. The greatest risk for intussusception was noted after the first dose of RotaShield. Data from a large-scale, prelicensure safety trial and postlicensure monitoring do not indicate an association between the current RotaTeq vaccine and intussusception. CDC assessed rotavirus vaccination coverage among U.S. infants during February 2006-May 2007 and examined adherence to the ACIP-recommended vaccination schedule. This report summarizes the results of that assessment, which indicated that, by May 15, 2007, nearly half of infants aged 3 months had received 1 dose of rotavirus vaccine, with the majority of doses administered according to ACIP recommendations. Health-care providers should remain vigilant in following the ACIP-recommended vaccination schedule for rotavirus vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18418345

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  7 in total

1.  Updated Statement on the use of Rotavirus Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-07-16

Review 2.  Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

3.  Unexpectedly high burden of rotavirus gastroenteritis in very young infants.

Authors:  H Fred Clark; Amy E Marcello; Diane Lawley; Megan Reilly; Mark J DiNubile
Journal:  BMC Pediatr       Date:  2010-06-11       Impact factor: 2.125

4.  Laboratory-Confirmed Rotavirus Disease in Utah Children: Clinical and Economic Impact of Rotavirus Vaccination.

Authors:  Angel Herrera Guerra; Chris Stockmann; Andrew T Pavia; Adam L Hersh; Emily A Thorell; Hsin Yi Weng; Kent Korgenski; Carrie L Byington; Krow Ampofo
Journal:  J Pediatric Infect Dis Soc       Date:  2012-06-22       Impact factor: 3.164

5.  Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine.

Authors:  H Fred Clark; Diane Lawley; Laura A Mallette; Mark J DiNubile; Richard L Hodinka
Journal:  Clin Vaccine Immunol       Date:  2009-01-21

6.  Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States.

Authors:  Girishanthy Krishnarajah; Kitaw Demissie; Patrick Lefebvre; Sunanda Gaur; Mei Sheng Duh
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: demand, supply and seasonality.

Authors:  Suchita A Lorick; Daniel Fishbein; Eric Weintraub; Pascale M Wortley; Grace M Lee; Fangjun Zhou; Robert Davis
Journal:  BMC Infect Dis       Date:  2009-11-03       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.